We have shown previously that stimulation of high-affinity GTP hydrolysis and inhibition of adenyiate cyciase activity by muscarinic agonists are mediated by pertussis toxin (IAP) substrates (G, and GJ in canine cardiac sarcolemma. We have now used the pertussis toxin-treated dog as a whole animal model in which G,-and G.-mediated biochemical mechanisms can be studied. Mongrel dogs were injected intravenously with IAP 48 hours prior to death and isolation of left ventricular sarcolemma. Treatment of the animal in vivo with the toxin prevented subsequent in vitro IAP-catalyzed ["PJADP-ribosylation of substrates in cardiac, erythrocytic, and renal cortical plasma membranes, suggesting that ADP-ribosylation occurred in vivo from endogenous substrate. Consistent with our previous results obtained by treating sarcolemma in vitro with IAP, muscarinic receptor-mediated stimulation of high-affinity GTP hydrolysis and inhibition of GTP-activated adenyiate cyciase activity were attenuated in sarcolemma purified from the toxin-treated animals. Proximal to adenyiate cyciase, guanine nucleotide regulation of muscarinic receptor affinity for agonists was also abolished in membranes from the toxin-treated animals. In addition, the ability of oxotremorine to attenuate GTP regulation of stimulation of adenyiate cyciase activity by magnesium ions was abolished in sarcolemma from the IAP-treated dogs. Thus, cardiac sarcolemma isolated from the IAP-treated animals displayed biochemical characteristics of an adenyiate cyciase system in which inhibitory regulatory pathways ' had been attenuated. The cardiac biochemical studies and the in vivo ADP-ribosylation of noncardiac IAP substrates also suggests considerable potential use of this model in the physiological and biochemical study of regulatory mechanisms mediated by GTP-binding proteins in other systems.
T he mammalian heart is functionally regulated by the opposing influences of the two limbs of the autonomic nervous system. 1 Parasympathetic activation of cardiac muscarinic receptors suppresses ventricular function, and this inhibitory effect is greater when (3-adrenergic receptors are activated (e.g., in the presence of sympathetic stimulation).'- 2 The biochemical mechanisms that mediate muscarinic effects are varied and include regulation of both cyclic AMP-dependent and cyclic AMP-independent processes. 13 "* Because the intracellular effects of catecholamines are largely mediated by increased synthesis of cyclic AMP by adenyiate cyciase [ATP pyrophosphate-ryase (cyclizing) E.C. 4.6.1.1], considerable experimental effort has been directed toward understanding the mech-anism^) by which muscarinic agonists attenuate the increase in cyclic AMP produced by 3-adrenergic agonists. It is now well established that stimulation and inhibition of adenyiate cyciase activity are mediated at the level of two similar yet unique GTP-binding proteins designated G, and G,, respectively. 7 Pertussis toxin (islet-activating protein, IAP) has been an important biochemical probe for the selective identification and functional modification of G, in several tissues. 7 Using nicotinamide adenine dinucleotide (NAD) as substrate, IAP catalyzes the covalent ADPribosylation of the a-subunit of G, (G^,), which causes a loss in the ability of G; to mediate the effects of inhibitory hormones. 8 G, and G ( interpose between receptors and adenyiate cyciase, and therefore, the functional integrity of the regulatory proteins affects processes both at the level of the autonomic receptors and at the level of adenyiate cyciase. We originally reported that muscarinic agonists antagonized the ability of guanine nucleoside 5'-triphosphates to regulate p-adrenergic receptor affinity for catecholamines in cardiac sarcolemma. 9 We have also demonstrated that muscarinic agonists attenuate GTP-activated adenyiate cyciase activity by a mechanism that is closely linked with GTP hydrolysis (GTPase activity). 9 "" In those studies, muscarinic stimulation of specific GTPase activity was inversely related to muscarinic inhibition of GTP-activated adenyiate cyciase activity, and the muscarinic effects on both processes were dependent on functional IAP substrates. We have now further extended these studjes using sarcolemma purified from the ventricles of control and IAP-treated dogs. Several inhibitory biochemical regulatory processes mediated by muscarinic receptors were attenuated or abolished in sarcolemma isolated from animals treated in vivo with LAP. In addition to further supporting our original hypotheses, the present report also suggests that the IAP-treated whole dog is an excellent candidate for studies in noncardiac tissues as a model system in which regulation of biochemical processes by inhibitory receptors linked to IAP substrates has been inactivated.
Table of Abbreviations
G, and G,, stimulatory and inhibitory guanine nucleotide binding and regulatory proteins of adenylate cyclase, respectively G,_, M-45,000 GTP-binding subunit of G, that is ADPribosylatea by cholera toxin G fa , M,-41,000 GTP-binding subunit of G, that is ADPribosylated by IAP G^, inhibitory dimeric complex of M, = 35,000 (f}) and M,~ 10,000 (y) subunits of G, and G, Gq, GTP-binding protein that regulates muscarinic receptor affinity for agonists in bovine brain G «» H~ 39,000 GTP-binding subunit of G o that is ADPribosylated by IAP LAP, islet-activating protein {Bordetella pertussis toxin) Gpp(NH)p, guanosine 5'-(P»7-iniino)-tnphosphate GTP7S, guanosine 5'-(0-tnio)-triphosphate ARF, ADP-ribosylation factor, a protein cofactor necessary for cholera toxin-catalyzed ADP-ribosylation of G,,, QNB, (± )-quinuclidinylbenzilate 
Materials and Methods

Preparation of IAP
Bordetella pertussis strain 165 was grown in modified Stainer-Sholte 12 medium as described by Hewlett et al. 13 Pertussis toxin was purified from the culture supernatants using hydroxylapatite and fetuinagarose chromatography using a modification of procedures described elsewhere 14 " 16 as communicated by Dr. Erik Hewlett of the University of Virginia, Charlottesville. Briefly, 7 1 culture supernatant were passed through a 200-ml column of hydroxylapatite that had been preequilibrated with 10 mM potassium phosphate (pH 9.0). The eluate from the pH-9 column was adjusted to pH 6.0 with HC1 and applied to a 200-ml column of hydroxylapatite that had been preequilibrated with 10 mM potassium phosphate (pH 6.0). This column was then washed sequentially with 500 ml of 100 mM potassium phosphate (pH 6.0) and 500 ml of 100 mM potassium phosphate (pH 7.0). Pertussis toxin was eluted from the column with 400 ml of 100 mM potassium phosphate (pH 7.0) containing 0.5 M NaCl. The resulting eluate was applied to a 35-ml column of fetuin-Sepharose. The column was washed with 105 ml of 100 mM potassium phosphate (pH 7.0) and 0.5 M NaCl. Pertussis toxin was eluted with 100 ml of 100 mM potassium phosphate (pH 7.0) and 0.5 M NaCl containing 3 M KSCN. The purified toxin was dialyzed and concentrated on an Amicon YM-10 ultrafiltration membrane (43 mm) (Danvers, Massachusetts) using 100 mM sodium phosphate (pH 7.0) and 0.5 M NaCl. Pertussis toxin was stable for at least 1 year when stored in frozen aliquots at -2 0° C.
Experimental Design
Conditioned mongrel dogs (22-30 kg) were injected with either 100 mM sodium phosphate (pH 7.0) and 0.5 M NaCl (control) or pertussis toxin (30 jig/kg i.v.) in the same buffer. The animals showed no obvious signs of discomfort or disease. Left ventricular sarcolemma was purified 48 hours postinjection of toxin and subjected to the indicated biochemical assays.
Preparation of Membranes
Purified cardiac left ventricular sarcolemma was prepared according to Jones et al 17 and Jones 18 from Procedure II membrane vesicles with the exception that 0.75 M NaCl and 10 mM /-histidine were substituted for 0.75 M KC1 and 5 mM /-histidine in the starting buffer. The total ouabain-sensitive Na + ,K + -ATPase activity of the purified sarcolemma was routinely 70-90 ^mol P/hr/mg protein.
Canine renal cortical plasma membranes were prepared using differential centrifugation essentially according to the method of Marx et al," exactly as described by Queener et al. 20 Canine erythrocytic plasma membranes were prepared by hypotonic lysis of erythrocytes obtained at the time of death and removal of heart and kidneys. Blood collection, lysis, and washing of membranes by centrifugation were exactly as described by Fleming and Ross. 21 All membranes were quick-frozen using a dry ice-acetone bath and stored at -8 0° C.
Adenylate Cyclase Assay
Adenylate cyclase activity was assessed by measuring the conversion of [a-32 P]ATP to cyclic [ 32 P]AMP, exactly as described previously. 10 Cyclic AMP formed during the reactions was isolated by the method of Salomon et al. 22 Results are expressed as the mean adenylate cyclase activity ±SEM of several different determinations, each using preparations of sarcolemma from individual hearts.
GTPase Assay
GTP hydrolysis was determined by measuring the release of 32 P ( from fr-^PJGTP, 23 exactly as recently described by us. 10 Specific GTPase activity of each membrane preparation was calculated as the difference between the mean total and nonspecific activities in duplicate determinations. Results are expressed as the mean specific GTPase activity ±SEM of several different determinations, each using preparations of sarcolemma from individual hearts.
[ 32 P]ADP-Ribosylation of G ia and G m
Covalent modification of the a-subunits of the LAP substrates was by modification of well-established procedures using [ 32 P]NAD as substrate. 24 -23 Purified sarcolemmal membranes (60 (ig) were incubated in 1.44 ml containing potassium phosphate (pH 8.0) 61 mM, NaCl 54 mM, dithiothreitol (DTT) 2.7 mM, MgCl 2 5 mM, thymidine 10 mM, GTP 0.1 mM, ATP 1 mM, phosphocreatine 3.3 mM, creatine phosphokinase 0.3 units/ml, [ 32 P]NAD (-10,000 cpm/pmol) 50 \iM, and 14.4 [Lg IAP (preactivated with 20 mM DTT, 30 minutes at 30° C). The reactions were initiated by the addition of PPJNAD, and intoxication proceeded for 30 minutes at 30° C. Intoxication was terminated by the addition of 4 ml ice-cold 0.25 M sucrose and 10 mM /-histidine, and the sarcolemmal membranes were sedimented at 40,000 rpm for 20 minutes in a Beckman 40 rotor (HSyOOOg^). Pelleted membranes were resuspended to a final concentration of 0.6 mg/ml and boiled for 5 minutes in gel dissociation medium 26 [Tris (pH 6.8) 62.5 mM, sodium dodecyl sulfate (SDS) 1.25% (vol/vol), P-mercaptoethanol 0.25% (vol/vol); grycerol 10% (vol/vol), and bromphenol blue 0.05% (vol/vol)].
SDS Polyacrylamide Gel Electrophoresis of IAP-Treated Sarcolemma
After intoxication with IAP, membranes were subjected to SDS polyacrylamide gel electrophoresis as described by Laemmli. M Samples containing 60 (xg protein were loaded onto each lane of a 12% resolving gel. The gels were run at 20 ma per gel for 30 minutes after the bromphenol blue dye front exited from the bottom of the gel. The gels were stained with Coomassie blue, destained, dried, and subjected to autoradiography using Du Pont Cronex Pelicula x-ray film and Du Pont Lightning Plus intensifying screens (Wilmington, Delaware).
Muscarinic Receptor Assays
The ability of guanine nucleotides to regulate muscarinic receptor affinity for agonists was determined in sarcolemmal membranes purified from control and toxin-treated animals in equilibrium binding assays using the antagonist ligand [ 3 H]quinuclidinylbenzilate ([ 3 H]QNB) n essentially as we have previously reported.'- 28 Briefly, the 0.1-ml assays contained Tris/HCl (pH 7.5) 40 mM, MgCl 2 10 mM, ascorbic acid 100 |xM, [ 3 H]QNB 5.5 nM, purified sarcolemma 6 \ig, and the indicated concentrations of GTP7S and oxotremorine. Binding was allowed to proceed to equilibrium for 10 minutes at 37° C. [ 3 H]QNB binding to membranes was quantitated by filtration on Whatman GF/C glass fiber filters using an M-24R cell harvester (Brandel, Gaithersburg, Maryland).
Statistical Analysis
Unless otherwise indicated, reported probability (p) values were derived from repeated measures analysis of variance. In some experiments, statistical significance was tested using Student's t test. Results Pertussis toxin treatment of the animals in vivo altered the ability of the toxin to catalyze the [ W P]ADPribosylation of G^ during subsequent in vitro exposure to the toxin and [ 32 P]NAD. IAP catalyzed the [ 32 P]ADPribosylation of G,,, in plasma membranes purified from canine cardiac left ventricles, erythrocytes, and renal cortex of the control animals ( Figure 1 ). As we have recently reported," two substrates for IAP were identified in the cardiac tissue: G, (M, = 41,000) and another protein corresponding to G o described in brain 29 -30 and heart 31 -32 (M r = 39,000). In contrast, the ability of IAP to label G^ was nearly abolished in all three membrane types examined from the animals treated with the toxin in vivo (Figure 1 ). G o was not identified in the erythrocytic and renal cortical plasma membranes ( Figure 1 ). [ 32 P]ADP-ribosylated IAP substrates in cardiac sarcolemma were isolated from polyacrylamide gels and quantitated using liquid scintillation spectrometry. Whereas IAP catalyzed the incorporation of 212.8 ± 38 fmol ADP-ribose/mg sarcolemmal protein in membranes from the hearts (n = 5) of control animals, only 23.8 ±8.8 fmol ADP-ribose/ mg sarcolemmal protein could be incorporated in membranes from the hearts (n = 7) of the animals that received IAP in vivo. Thus, intravenous injection of IAP effectively catalyzed the endogenous ADPribosylation of cardiac G ; and G o (p<0.001).
We have recently shown that the ability of muscarinic receptor agonists to inhibit adenylate cyclase activity is closely linked to their ability to stimulate specific, high-affinity GTP hydrolysis displayed by canine cardiac sarcolemma. 1011 In the present study, in vivo pretreatment of dogs with IAP markedly reduced oxotremorine stimulation of specific GTPase activity in subsequently purified sarcolemma, and adenylate cyclase activity was refractory to inhibition by the muscarinic agonist. Concentration-effect curves for oxotremorine stimulation of specific GTPase activity are shown in Figure 2 . Oxotremorine stimulated specific GTPase activity in a concentration-dependent manner in sarcolemma purified from both control and IAP-treated animals (p<0.001). However, maximal muscarinic stimulation of specific GTPase activity was markedly reduced in membranes from the hearts of the toxin-treated animals (17.1%) compared with that seen in the control membranes (70.2%). Although oxotremorine stimulated GTPase activity in sarcolemma from the IAP-treated animals, muscarinic stimulation was significantly reduced in membranes from the IAPtreated animals at essentially all concentrations tested (j><0.001). In vivo ADP-ribosylation of the LAP substrates thus attenuated the ability of oxotremorine to stimulate the specific GTPase activity of subsequently isolated cardiac sarcolemma. That muscarinic stimulation of GTPase activity was attenuated in sarcolemma from the IAP-treated dogs suggested that inhibition of GTP-stimulated adenylate cyclase activity might be reduced in membranes from the treated animals. Concentration-effect curves for oxotremorine inhibition of GTP-stimulated adenylate cyclase activity are shown in Figure 3 . Oxotremorine inhibited GTP-stimulated adenylate cyclase activity in a concentration-dependent manner in sarcolemma purified from both control and IAP-treated animals (p< 0.001). Maximal muscarinic inhibition of GTPstimulated adenylate cyclase activity of 84.3% in the control membranes was reduced to 20.4% in membranes from the hearts of the toxin-treated animals. Although oxotremorine somewhat inhibited GTPstimulated adenylate cyclase activity in sarcolemma from the IAP-treated animals, muscarinic inhibition was significantly reduced in membranes from the IAP-treated animals at all concentrations tested (p< 0.001). In summary, IAP-cataryzed ADP-ribosylation of sarcolemmal substrates in vivo attenuated the ability of oxotremorine to both stimulate specific GTP hydrolysis and inhibit GTP-stimulated adenylate cyclase activity in the subsequently isolated cardiac membranes.
It is well established that guanine nucleoside 5'triphosphates regulate the affinity of many cell surface receptors for their agonists, and this has been demonstrated for autOHGrnic receptors in purified canine cardiac sarcolemma. 9 -33 Competitive radioligand binding assays using [ 3 H]QNB were used to assess the effect of in vivo IAP treatment of the animals on the ability of guanine nucleotides to regulate muscarinic receptor FIGURE 4 . Effects of in vivo islet-activating protein (IAP) treatment on the ability of GTPyS to regulate muscarinic receptor affinity for agonist in purified sarcolemma (SL). Specific muscarinic receptor binding was determined in sarcolemma purified from hearts taken from control (control SL) and IAPtreated dogs (IAP SL) as described in "Materials and Methods." The assays contained 5.6 nM f'HJQNB and the indicated concentrations of oxotremorine. Where indicated, 100 UJW GTPyS was also present in the assays. The amount of oxotremorine bound was determined from the amount of / 3 H]QNB displaced from the membranes at each concentration tested. Lines, nonlinear least-squares fit of the data to either a two-site (control) or one-site (IAP) mass action binding model as described in the text. affinity for agonists in subsequently isolated sarcolemma. Binding of [ 3 H]QNB to sarcolemma from the hearts of both control and IAP-treated animals Was to a single class of receptors (K d = 10-15 pM, n = 5). Although in vivo IAP treatment of the animals had no effect on the affinity of muscarinic receptors for [ 3 H]QNB, toxin pretreatment of the animals abolished the ability of GTP7S to regulate muscarinic receptor affinity for agonist ( Figure 4 ). In sarcolemma from the control animals, specific oxotremorine binding to muscarinic receptors indicated complex binding kinetics (pseudo-Hill coefficient, n<l) characteristic of autonomic receptors in the absence of regulation by guanine nucleotides (Figure 4 ). Oxotremorine binding to the cardiac muscarinic receptors was evaluated further with nonlinear least-squares curve-fitting analysis of the data using either a two-site (control) or one-site (IAP) mass action binding model according to the equation:
,-., K A + [free] Muscarinic receptors in purified sarcolemnia were assayed in the absence and presence of 100 ^.M GTPyS as described in "Materials and Methods." The results of nonlinear least-squares curve-fitting analysis of the oxotremorine binding isotherms depicted in Figure 4 are summarized for two representative experiments. The constants above indicate the dissociation constants for the high-( H Kj) and low-C-Kj) affinity states of the receptors and the corresponding receptor density of each affinity class ("N and L N). The Kj values were calculated from the binding data by the method of Cheng and Prusoff. 44 (The K,, for [ 3 H]QNB was 15.3 pM, and the concentration of [ 3 H]QNB in the assays was 5.5 nM.) Asymmetric confidence intervals shown in parentheses were calculated according to Johnson and Frasier. 34 IAP, islet-activating protein.
TABLE 2. Effect of In Vivo IAP Treatment on Gnanine Nucleotide Inhibition of Forskolin-Stimulated Adenyiate Cyciase Activity
Adenyiate cyciase activity (pmol cAMP/min/mg protein) Additions Control LAP treated None 3,038 + 301 2,151 ±322 0.1 /xM GTPyS 2,578±220 (-14.5%) 2,057±315 (-4,3%) Adenyiate cyciase activity was determined as described in "Materials and Methods" in the presence of 0.25 mM ATP, 1 mM MgCl 2 > Md 10 fiM forskolin. Sarcolemma purified from the hearts of control and IAP-treated.animals was assayed in the absence and presence of 0.1 pM GTP7S. The percent inhibition due to GTPyS is indicated in parentheses.
IAP, islet-activating protein.
where R is the concentration of receptor molecules, i is an index referring to each of the m different classes (affinities) of receptors, n x is the number of receptors in each of the i affinity states, and K di is the corresponding dissociation constant for each of the affinity states of the receptors. 34 Sarcolemma purified from the hearts of control animals displayed two populations of muscarinic receptors with high-and low-affinity states differing approximately 100-fold in relative affinity for oxotremorine ( Table 1 ). In the absence of regulation by guanine nucleotide, 61% of the receptors displayed high-affinity binding ( H K d = 1.4 nM), while 39% were in the low-affinity state ( L K d = 76.0 nM). The presence of GTP7S shifted the majority (67%) of the receptors into the low-affinity state ( L K d = 135.9 nM), with 33% of the receptors remaining in a relatively high-affinity state ( H K d = 20.3 nM). Therefore, GTP7S converted the majority of the high-affinity receptors to the low-affinity state in sarcolemma from the hearts of control animals. In contrast, guanine nucleotide regulation of muscarinic receptor affinity for oxotremorine was totally absent in sarcolemma from the hearts of IAP-treated animals ( Figure 4 and Table 1 ). Leastsquares analysis revealed that 100% of the receptors (~2 pmol/mg protein) were in the low-affinity state ( L K d = 117.9 nM), and the addition of 100 LIM GTP7S resulted in no significant change in affinity ( L K d = 140.6 nM). Furthermore, the pseudo-Hill coefficient for oxotremorine binding to muscarinic receptors in sarcolemma from the IAP-treated animals was approximately 1.0, indicating simple binding to a homogeneous population of receptors. ADP-ribosylation of the cardiac IAP substrates thus totally abolished GTP7S regulation of muscarinic receptor affinity for oxotremorine. Nonhydroryzable GTP analogues characteristically inhibit forskolin-stimulated adenyiate cyciase activity 15-30% in membranes that display functional G;, 35 and we have shown previously that Gpp(NH)p inhibits the forskolin-stimulated canine cardiac enzyme. 10 In sarcolemma from the control animals, 0.1 \LM GTP7S inhibited adenyiate cyciase activity in the presence of 10 u,M forskolin by 14.5% ( Table 2 ). In contrast, GTP-yS inhibited the forskolin-stimulated enzyme by only 4.3%. The ability of GTP7S to inhibit the forskolin-stimulated enzyme was significantly reduced (p < 0.05) in membranes from the toxin-treated animals ( Table 2) .
Finally, muscarinic effects on the ability of GTP and magnesium ions to regulate adenyiate cyciase activity were examined in sarcolemma from the hearts of control and IAP-treated animals. In sarcolemma from both control and IAP-treated animals, MgCl 2 augmented GTP-stimulated adenyiate cyciase activity in a concentration-dependent manner (p< 0.001, Figure  5 ). Although 10 LIM oxotremorine markedly inhibited GTP-stimulated adenyiate cyciase activity at all concentrations of MgCl 2 tested in the control sarcolemma (/?< 0.001), muscarinic inhibition of the enzyme was essentially abolished in sarcolemma from the IAPtreated animals ( Figure 5 ).
Discussion
Treatment of intact dogs with IAP resulted in alterations in the interactions of the components of the hormone-regulated adenyiate cyciase system in cardiac 
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FIGURE 5. Effects of in vivo islet activating protein (IAP) treatment on regulation of adenyiate cyciase activity by oxotremorine (OXO) and MgCl 2 in sarcolemma (SL) purified from control and IAP-treated dogs.
Adenyiate cyciase activity was assessed as described in "Materials and Methods. " The assays contained the indicated concentrations of oxotremorine (OXO) and MgCl 2 . The increment in adenyiate cyciase activity due to the presence of 10 \xM GTP is shown, (n = 3, control; n = 2, IAP treated,) sarcolemma purified from the hearts taken from these dogs. We have previously shown that muscarinic agonists modulate both ^-adrene^gic receptor affinity for catecholamines 9 and GTP-activation of adenylate cyclase. 9 "" It has been shown that the biochemical effect of IAP is the ADP-ribosylation of the a-subunit of G, (and possibly G o ), and this modification by the toxin results in the inactivation of the ability of the IAP substrates to mediate inhibition of adenylate cyclase activity. 7 -8 The present report describes the attenuation of biochemical mechanisms mediated by IAP substrates in cardiac sarcolemma isolated from the hearts of animals treated in vivo with the toxin.
In vivo ADP-ribosylation of G fa and G M from endogenous NAD was confirmed by the inability of the substrates to be [ w P]ADP-ribosylated on subsequent exposure to the toxin and [ 32 P]NAD in vitro (Figure 1 ). The ability of oxotremorine to stimulate high-affinity GTPase activity and inhibit GTP-activated adenylate cyclase activity was markedly attenuated or abolished in membranes from the toxin-treated animals ( Figures  2 and 3 ). In addition, the ability of GTP7S to regulate muscarinic receptor affinity for agonists was abolished in membranes from the toxin-treated animals ( Figure  4 and Table 1 ). Thus, several biochemical regulatory systems related to adenylate cyclase were interrupted by in vivo ADP-ribosylation of cardiac sarcolemma with IAP: muscarinic stimulation of GTPase activity, muscarinic inhibition of adenylate cyclase activity, inhibition of forskolin-stimulated adenylate cyclase activity by GTP7S, and, proximal to adenylate cyclase, guanine nucleotide regulation of muscarinic receptor affinity for agonists.
Apart from the effects of in vivo IAP administration to uncouple guanine nucleotide regulation of oxotremorine binding to subsequently isolated cardiac muscarinic receptors, it was of interest to us that GTP-yS did not shift 100% of the receptors from the high-affinity state to the low-affinity state in the sarcolemma from the control animals ( Figure 4 and Table 1 ). Rather, 33% of the receptors remained in a relatively high, intermediate affinity state ("K d = 20.3 nM) in the presence of GTP-yS. Because the data were obtained in the presence of MgCl 2 and a high concentration of GTP7S (100 M-M), it seemed unlikely that the intermediate state of receptor affinity resulted simply from an incomplete effect of GTP-yS. We have consistently observed that approximately one third of the receptors do not shift completely to the low-affinity state but rather shift to an affinity intermediate between the affinities displayed in the absence of guanine nucleotide. Furthermore, this observation was true regardless of whether the guanine nucleotide was GTP7S or Gpp(NH)p (data not shown).
Although there is substantial precedent in the literature for muscarinic receptors existing in three affinity states, 36^1 the present data did not allow strict differentiation between the possibilities of two or three affinity states of the canine cardiac receptors. Birdsall et a P first demonstrated mammalian neuronal muscarinic receptors existing in three affinity states, and Hosey et al 40 have observed three affinity states of the chick cardiac muscarinic receptor. In addition, treatment of chicks with IAP 48 hours before preparation of cardiac membranes resulted in elimination of the highest affinity state of the muscarinic receptors and increases in the proportions of receptors in the intermediate-and low-affinity states. 40 The K d of the high-affinity state of the canine cardiac receptor (1.4 nM) was similar to that reported in other cardiac tissue, 40 but lower-affinity states did not differ to the degree reported in other systems. For example, the highest and lowest affinity states described in the mammalian neuronal and chick cardiac membranes differed by two to three orders of magnitude and required fitting of the data to a three-site binding model. In contrast, the high-and low-affinity states of the muscarinic receptors in the present study differed by two orders of magnitude or less and did not require the hypothesis of a third affinity state for adequate fit of the data. It can be seen in Table 1 that the confidence interval for the intermediate affinity state of the receptor in the presence of GTP7S( H K d = 11.SM0.9 nM) overlapped with that of the low-affinity state seen in the absence of guanine nucleotide ( L K d = 38.0-152.9 nM). Thus, it cannot be stated unequivocally whether the canine receptors actually exist in three affinity states that differ by a factor of 10 or less or whether the receptors exist in only two affinity states. Regardless of the strict interpretation of the oxotremorine displacement curves, the important conclusion remains that the highest affinity state of the receptors was eliminated by either the presence of GTP-yS or by complete uncoupling of the receptors from LAP substrate(s) by administration of the toxin to the animals in vivo.
In addition to G^, we have shown that IAP catalyzes the [ 32 P]ADP-ribosylation of an additional substrate in canine cardiac sarcolemma (Figure 1 and J. W. Fleming and A.M. Watanabe"). The additional IAP substrate is analogous to G^, described previously in bovine brain, 2930 chick heart, 31 and rabbit heart. 32 Although G M has not been directly demonstrated to affect adenylate cyclase activity, 42 G o has been shown to regulate muscarinic receptor affinity for agonists. 43 We have recently shown that the most significant mechanism for muscarinic effects on adenylate cyclase activity in canine cardiac sarcolemma is mediated indirectly by inhibition of activated G,,, (G M -GTP).'°The mechanism of inhibition is closely linked to the hydrolysis of GTP 9 "" and may be related to the inhibitory receptorcatalyzed release of functionally similar, if not identical, G^-subunits from G, and G o in the presence of GTP. 7 Ivatada and coworkers 8 have shown that ADPribosylation of IAP substrates increases the affinity of the a-subunits for the p-y-subunits, thus reducing the ability of inhibitory P7-subunits to dissociate from the G proteins in response to inhibitory receptor agonists. It appears likely that the biochemical alterations seen in sarcolemma purified from the hearts of IAP-treated animals result from ADP-ribosylation of the a-subunits of both G, and G o . Present experiments are directed toward selective definition of the relative roles of G, and G o in the mechanism of inhibitory regulation of receptor affinity and inhibition of adenylate cyclase activity.
It is important to note that studies of inhibitory regulation are not limited to in vitro study or to particular tissues in the model used for the present studies. The IAP-treated dog appears to be an excellent whole animal model in which biochemical mechanisms mediated by LAP substrates can be studied. The IAP-treated dog model is limited only by the accessibility of the toxin to its substrates. The present study indicates that G^ was ADP-ribosylated in vivo in three tissues examined: cardiac, erythrocytic, and renal cortical. Previous use of LAP in whole animals has been limited to small animals of the rodent family. However, the dog is a preferred model for many physiological and biochemical investigations, and the IAP-treated animal is an excellent candidate for such studies. Our preliminary results have indicated complete loss of vagal control of chronotropy in the IAP-treated dogs.* Electrical stimulation of either the right or left vagus nerve produced none of the characteristic electrocardiographic alterations observed in the control animals (e.g., cessation of sinus node activity).
Although our data to date indicate that essentially all of the toxin substrates were labeled in vivo, it is possible that a small fraction of LAP substrates remained unmodified and resulted in the small residual effects of oxotremorine seen on GTPase and adenylate cyclase activities. However, it seems unlikely that a small unlabeled pool of inhibitory G proteins will significantly complicate further physiological studies using this model. Rather, the IAP treatment rendered enzymatic response to oxotremorine highly significantly attenuated when compared with control sarcolemma. Furthermore, guanine nucleotide regulation of muscarinic receptor affinity was completely abolished in membranes from the toxin-treated animals, as was responsiveness of the hearts to vagal stimulation in intact animals. It is, therefore, expected that use of the IAP-treated dog will contribute substantially to the understanding of processes mediated by G ( and G o and also provide a model for answering new questions likely to arise regarding the effects of chronic inactivation of mechanisms mediated by these proteins.
